CN113521015B - 一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 - Google Patents
一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN113521015B CN113521015B CN202011130517.4A CN202011130517A CN113521015B CN 113521015 B CN113521015 B CN 113521015B CN 202011130517 A CN202011130517 A CN 202011130517A CN 113521015 B CN113521015 B CN 113521015B
- Authority
- CN
- China
- Prior art keywords
- freeze
- drying
- 4d5fv
- fusion protein
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011130517.4A CN113521015B (zh) | 2020-10-21 | 2020-10-21 | 一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011130517.4A CN113521015B (zh) | 2020-10-21 | 2020-10-21 | 一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113521015A CN113521015A (zh) | 2021-10-22 |
CN113521015B true CN113521015B (zh) | 2022-12-06 |
Family
ID=78094468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011130517.4A Active CN113521015B (zh) | 2020-10-21 | 2020-10-21 | 一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113521015B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116023501A (zh) * | 2021-10-25 | 2023-04-28 | 三生国健药业(上海)股份有限公司 | 一种抗her2的免疫毒素分子、及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
WO2015125501A1 (ja) * | 2014-02-24 | 2015-08-27 | 国立大学法人名古屋大学 | タンパク質凍結保存用保護剤 |
CN106589131A (zh) * | 2015-10-19 | 2017-04-26 | 山东省生物制品研究所 | 融合蛋白4D5Fv-PE25及其制备方法和用途 |
CN109111498A (zh) * | 2018-09-12 | 2019-01-01 | 山东省生物制品研究所 | 一种减少蛋白在protein L凝胶层析中形成多聚体的方法 |
-
2020
- 2020-10-21 CN CN202011130517.4A patent/CN113521015B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
WO2015125501A1 (ja) * | 2014-02-24 | 2015-08-27 | 国立大学法人名古屋大学 | タンパク質凍結保存用保護剤 |
CN106589131A (zh) * | 2015-10-19 | 2017-04-26 | 山东省生物制品研究所 | 融合蛋白4D5Fv-PE25及其制备方法和用途 |
CN109111498A (zh) * | 2018-09-12 | 2019-01-01 | 山东省生物制品研究所 | 一种减少蛋白在protein L凝胶层析中形成多聚体的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113521015A (zh) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Benoit et al. | Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home | |
CA1100872A (en) | Method of producing intravenously injectable gamma globulin | |
CN101291659A (zh) | 包含水难溶性药剂和抗微生物剂的组合物 | |
NL8000291A (nl) | Werkwijze voor het bereiden van interferon type ii, de therapeutische toepassing van interferon type ii en de farmaceutische preparaten op basis hiervan. | |
CN100475840C (zh) | 胡蜂抗菌肽及其制备方法和应用 | |
US4250084A (en) | Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it | |
CN113521015B (zh) | 一种融合蛋白4D5Fv-PE25冻干剂及其制备方法和应用 | |
CN104043104A (zh) | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 | |
US4163780A (en) | Ks-2-a | |
WO2020192693A1 (zh) | 抗Her2抗体药物偶联物药物制剂 | |
EP3453718B1 (en) | Use of protein p8 derived from lactic acid bacteria as an anti-cancer agent | |
CA1135640A (en) | Anti-tumor substance and process for preparing the same | |
CN116102640A (zh) | 重组乳铁蛋白衍生肽及其在提高免疫力方面的应用 | |
WO2016011878A1 (zh) | 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用 | |
JPH0753667B2 (ja) | 骨髄移植療法補助剤 | |
CN103040910A (zh) | 一种鹿瓜多肽脂质体注射剂 | |
WO2014121611A1 (zh) | 一种稳定的诺卡沙星粉针冻干剂 | |
CN110897998A (zh) | 一种同时载有疏水性药物和亲水性药物的基因工程多肽纳米水凝胶及其制备方法 | |
NZ235153A (en) | Stabilised alpha-interferon compositions | |
US20220081682A1 (en) | Botulinum toxin producing method | |
CN106389359A (zh) | 供注射用的贝利司他药物组合物及其制备方法 | |
CN102327239A (zh) | 鲑鱼降钙素纳米脂质体注射剂及制备方法 | |
RU2270669C2 (ru) | Лекарственные средства с содержанием ксеногенных олиго- или/и полирибонуклеотидов | |
JPS6019720A (ja) | ヒト内来性癌制御因子およびその製造法 | |
RU2326944C2 (ru) | Способ получения и препарат аналога рекомбинантного интерферона гамма человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Peng Yanjie Inventor after: Zhang Lin Inventor after: Zhong Lijun Inventor after: Fan Jiajin Inventor after: Li Feng Inventor after: Cao Qianggeng Inventor after: Zhang Hongrui Inventor before: Peng Yanjie Inventor before: Cao Qianggeng Inventor before: Zhong Lijun Inventor before: Zhang Lin Inventor before: Fan Jiajin Inventor before: Li Feng Inventor before: Zhang Hongrui |
|
GR01 | Patent grant | ||
GR01 | Patent grant |